Personalized Medicine – News and Features

Collaboration will select patient candidates for novel investigational non-small cell lung cancer therapy.

Agreement covers testing of Silicos lead compounds on human isogenic cell-lines comprising specific genotypes targeted by the compound series.

caCORRECT and omniBioMarker are being made available to cancer researchers to remove artifacts and identify and validate biomarkers from microarray data.

Newly identified genetic marker that predicts response to hepatitis C treatments may also explain difference in rates of response among racial and ethnic groups.

New method demonstrated by a team supported by NIH may help in efforts to pinpoint disease-causing genes.

Cellular Dynamics International (CDI) announced today the appointment of Leroy Hood, M.D., Ph.D., and George Church, Ph.D., two of the world’s leading scientists in molecular biotechnology and genomics, to the company’s scientific advisory board. Hood and Church join stem cell pioneer James Thomson, V.M.D., Ph.D., to advise the company on strategic plans for developing induced pluripotent stem (iPS) cells into drug discovery tools and, eventually, personalized therapeutics.

The collaboration is aimed to sequence genomic regions associated with psychiatric disease.

The agreement covers the licensing of certain X-MAN cell lines including major cancer causing genes and their matched normal genetic backgrounds.

Under the terms of the agreement Merck has committed to a five-year $145 million contract to purchase genomic analysis services from Covance.

The SBIR grant will be used to develop a database and systems biology tool-set specifically designed for pharmacogenomic research.